The first randomized phase II trial evaluating ablation plus immunotherapy in advanced NSCLC with oligo-residual disease
The BOOSTER study offers the first prospective evidence that adding local ablation to ongoing anti–PD-1/L1 therapy can improve disease control in advanced NSCLC patients with oligo-residual disease. ...
Hygea Co-Ablation System for Lung Tumors: Clinical Evidence from a Large Retrospective Study
New clinical data published in European Journal of Radiology demonstrate that the Hygea Co-Ablation System is a safe and feasible option for the treatment of malignant lung tumors. In more than 200 tr...
EN 